Retail sales of inhalation devices in European countries: So much for a global policy
Retail sales of inhalation devices in European countries: So much for a global policy
复制标题
DOI：
10.1016/j.rmed.2011.03.012
复制
发表时间：
2011-07-01
影响因子：
4.3
通讯作者：
Crompton, G. K.
中科院分区：
文献类型：
--
作者：
Lavorini, F.;Corrigan, C. J.;Crompton, G. K.
目的：为了评估的零售额的压力计量吸入器（pMDIs），干粉吸入器（DPI）和液体雾化在16个欧洲countries.Methods：零售销售数据有关的pMDIs，DPI和液体雾化提供短效和长效支气管扩张剂，皮质类固醇和组合之间的2002年和2008年从IMS的销售数据库。IMS数据库确保批发商的库存销售准确匹配的零售药店，并包括直接从药品制造商，专业批发商和分销cooperations.Results的小组药房采购：平均吸入器零售销售（表示为总销售额的百分比）为47.5%的pMDI，39.5%的DPI和13%的雾化器。与DPI销售占主导地位的其他国家相比，英国和匈牙利的pMDI销售量最大的国家之间的吸入器销售分布存在显著差异。雾化液体在意大利的销量很高。pMDI是最常处方的支气管扩张剂吸入器。相比之下，DPI的零售额与吸入性皮质类固醇的pMDI的零售额相似，并且在吸入器与长效β（2）-激动剂和皮质类固醇相结合的情况下更高。结论：我们发现欧洲国家之间的吸入器处方具有高度的变异性。不同的健康政策、成本、健康保险问题、制药/商业方面以及处方者和患者的偏好可能解释了这种差异。我们建议在整个欧洲需要更统一的、以结果为导向的吸入器处方实践，以提高阻塞性气道疾病治疗的疗效和成本效益。(C)2011爱思唯尔有限公司保留所有权利。
Objective: To evaluate the retail sales of pressurised metered-dose inhalers (pMDIs), dry-powder inhalers (DPIs) and liquids for nebulisation in 16 European countries.Methods: Retail sales data relating to pMDIs, DPIs and liquids for nebulisation delivering short- and long-acting bronchodilators, corticosteroids and combinations between 2002 and 2008 were obtained from the IMS sales database. The IMS database ensured that wholesalers' stock sales accurately matched that of retail pharmacies and included purchases by panel pharmacies directly from pharmaceutical manufacturers, specialist wholesalers and distribution cooperatives.Results: Mean inhaler retail sales (expressed as percentages of total sales) were 47.5% for pMDIs, 39.5% for DPIs and 13% for nebulisers. The distribution of inhaler sales differed significantly between the countries with pMDI sales greatest in the United Kingdom and Hungary compared to other countries, where DPI sales prevailed. Sales of nebulisation liquids were high in Italy. The pMDI was the most frequently prescribed inhaler for bronchodilators. In contrast, retail sales of DPIs were similar to those of pMDIs for inhaled corticosteroids, and higher in the case of inhalers with combined long-acting beta(2)-agonist and corticosteroid.Conclusion: We found a high degree of variability in inhaler prescription between European countries. Differing health policies, costs, health insurance issues, pharmaceutical/commercial aspects and prescribers' and patients' preferences may explain this variation. We suggest a need for more uniform, outcome-led inhaler prescribing practice across Europe to improve the efficacy and cost effectiveness of the treatment of obstructive airways diseases. (C) 2011 Elsevier Ltd. All rights reserved.